AqueSys, Inc. Announces XEN Gel Stent U.S. Clinical Trial Enrollment Is Complete

ALISO VIEJO, Calif.--(BUSINESS WIRE)--AqueSys, Inc., the developer of minimally invasive stent technology for the treatment of glaucoma, announced today the completion of enrollment in the U.S. investigational study of the XEN 45 Gel Stent. The XEN Gel Stent is the first glaucoma device designed to achieve similar intraocular pressure (IOP) reduction as traditional subconjunctival trabeculectomy and tube shunt procedures through a minimally invasive technique with less associated surgical and post-operative risk.

Help employers find you! Check out all the jobs and post your resume.